Philip James Wealth Mangement LLC Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Philip James Wealth Mangement LLC grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 43.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,659 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,205 shares during the quarter. Philip James Wealth Mangement LLC’s holdings in Jazz Pharmaceuticals were worth $1,313,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in JAZZ. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the period. Ellsworth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after acquiring an additional 149 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Jazz Pharmaceuticals by 2.2% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock valued at $868,000 after acquiring an additional 155 shares during the last quarter. Cooper Financial Group boosted its position in shares of Jazz Pharmaceuticals by 3.7% during the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 156 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after acquiring an additional 165 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $133.96 on Monday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $138.27. The stock has a market capitalization of $8.10 billion, a PE ratio of 18.87, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. The stock’s 50 day moving average price is $123.47 and its 200-day moving average price is $117.27.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 5,053 shares of company stock valued at $617,442. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JAZZ. Piper Sandler reiterated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $130.00 to $170.00 in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, TD Cowen decreased their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $180.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.